Liping Liu | Chief Executive Officer And Chief Scientific Officer
Shenzhen HighTide Biopharmaceutical Ltd. | China

Liping Liu, Chief Executive Officer And Chief Scientific Officer, Shenzhen HighTide Biopharmaceutical Ltd.

Liping Liu is the founder, CEO & CSO of HighTide Therapeutics, a globally focused company to develop therapeutics for chronic non-viral liver diseases, gastrointestinal diseases and metabolic disorders with large and unsatisfied markets needs. 

The company’s lead drug is a first-in-class new molecular entity, currently in Phase II trials for the treatment of primary sclerosing cholangitis (PSC), a rare disease with no approved therapy, and nonalcoholic steatohepatitis (NASH), an asymptomatic, silent disease emerging into a public health crisis worldwide.   

Prior to founding HighTide, Dr. Liu held positions as the Director of R&D, Stealth Biotherapeutics Inc.; Head of Proteomics, ATCC; Senior Manager of R&D, MannKind Corp, and the Director of Antigen Discovery, CTL ImmunoTherapies Corp.

Dr. Liu received her doctoral degree from Nankai University, completed post-doctoral training in University of Toronto, and received MBA degree from Johns Hopkins University Carey Business School.


Phar-East Day 2 @ 11:40

East meets west, the quest to cure

last published: 19/Feb/19 03:35 GMT

back to speakers






For speaking, sponsorship and exhibition opportunities contact
Tel: +65 6322 2738